Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study

Autor Silva, Giovanni Faria Google Scholar
Villela-nogueira, Cristiane A. Google Scholar
Mello, Carlos Eduardo Brandao Google Scholar
Soares, Elza Cotrim Google Scholar
Coelho, Henrique Sergio M. Google Scholar
Ferreira, Paulo Roberto Abrão Autor UNIFESP Google Scholar
Ruiz, Fernando Jose Goes Google Scholar
Instituição Universidade Estadual Paulista (UNESP)
Universidade Federal do Rio de Janeiro
Universidade Estadual de Campinas (UNICAMP)
Universidade Federal de São Paulo (UNIFESP)
Pontificia Universidade Catolica de São Paulo
Resumo Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.
Palavra-chave Hepatitis C
Advanced fibrosis
Peginterferon
Ribavirin
Idioma Inglês
Data de publicação 2014-01-01
Publicado em Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014.
ISSN 1413-8670 (Sherpa/Romeo, fator de impacto)
Publicador Brazilian Society of Infectious Diseases
Extensão 48-52
Fonte http://dx.doi.org/10.1016/j.bjid.2013.05.007
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000332911100008
SciELO S1413-86702014000100048 (estatísticas na SciELO)
Endereço permanente http://repositorio.unifesp.br/handle/11600/8202

Exibir registro completo




Arquivo

Nome: S1413-86702014000100048.pdf
Tamanho: 624.1KB
Formato: PDF
Descrição:
Abrir arquivo

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta